FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

Date publication

janvier 2015

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain

Tous les auteurs :
Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R, Terrebonne E, De La Fouchardière C, Manfredi S, Solub D, Lécaille C, Thirot Bidault A, Carbonnel F, Taieb J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25037971

Résumé

First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (LAPA).

Mots clés

Adenocarcinoma, drug therapy, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Camptothecin, administration & dosage, Cisplatin, administration & dosage, Deoxycytidine, administration & dosage, Female, Fluorouracil, administration & dosage, Follow-Up Studies, Humans, Irinotecan, Leucovorin, administration & dosage, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, drug therapy, Neoplasm Staging, Pancreatic Neoplasms, drug therapy, Prognosis, Prospective Studies, Survival Rate

Référence

Ann. Surg. Oncol.. 2015 Jan;22(1):295-301